Consensus on the secondary prevention of primary liver cancer-Reference-Cited by-同舟云学术

Consensus on the secondary prevention of primary liver cancer

Published:2021-11-30 Issue:6 Volume:15 Page:1289-1300
ISSN:1936-0533
Container-title:Hepatology International
language:en
Short-container-title:Hepatol Int

Author:

Nan Yuemin^ORCID,Xu Xiaoyuan,Gao Yanhang,Wang Rongqi,Li Wengang,Yang Ming,Liu Lingdi,Duan Zhongping,Jia Jidong,Wei Lai,Zhuang Hui,Ding Huiguo,Duan Zhongping,Fan Jiangao,Fang Qinmao,Gao Yanhang,Hu Peng,Jia Jidong,Li Wengang,Liu Jingfeng,Niu Junqi,Nan Yuemin,Shang Jia,Wang Rongqi,Wei Lai,Yu Yanyan,Zhang Yuguo,Zhao Suxian,Zhou Jian,Zhao Weifeng,Xu Xiaoyuan,Xie Chuanmiao,Xie Wen,Yang Ming,Zhuang Hui,

Abstract

AbstractTo standardize the effective prevention, surveillance, and diagnosis of primary liver cancer, the Chinese Society of Hepatology, Chinese Medical Association, invited clinical experts and methodologists to develop the Consensus on the Secondary Prevention of Primary Liver Cancer, which was based on the clinical and scientific advances on hepatocellular carcinoma. The purpose is to provide a current basis for the prevention, surveillance, and early diagnosis of primary liver cancer in patients with chronic liver diseases.

Publisher

Springer Science and Business Media LLC

Subject

Hepatology

Link

https://link.springer.com/content/pdf/10.1007/s12072-021-10259-7.pdf

Reference60 articles.

1. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–926

2. Schünemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336:1106–1110

3. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249

4. Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35:2155–2166

5. Mu X, Wang W, Jiang Y, Feng J. Patterns of comorbidity in hepatocellular carcinoma: a network perspective. Int J Environ Res Public Health. 2020;17:3108

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploiting gender-based biomarkers and drug targets: advancing personalized therapeutic strategies in hepatocellular carcinoma;Frontiers in Pharmacology;2024-06-20

2. Exploring the Role of ENO1 in Regulating Cell Proliferation and Cell Cycle in Hepatocellular Carcinoma: Insights from Proteomic Analysis;2024-04-22

3. Physical activity and exercise in liver cancer;Liver Research;2024-03

4. Advancements of the CRISPR/Cas9 System in the Treatment of Liver Cancer;Current Protein & Peptide Science;2024-02

5. Application of the Multi-Omics Liquid Biopsy Method M2P-HCC in Early Liver Cancer Screening for High-Risk Individuals with Hepatitis B-Related Liver Cancer;Diagnostics;2023-07-26